**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 90414

**Manuscript Type:** EDITORIAL

**Circulating tumor cells as prognostic marker in pancreatic cancer**

Yakar M *et al*. Circulating tumor cells in pancreatic cancer

Melek Yakar, Durmuş Etiz

**Melek Yakar,** Department of Radiation Oncology, Osmangazi University, Eskişehir 26040, Turkey

**Durmuş Etiz,** Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir 26040, Turkey

**Author contributions:** Yakar M and Etiz D contributed to this paper; Yakar M designed the overall concept and outline of the manuscript; Etiz D contributed to the discussion and design of the manuscript; Yakar M and Etiz D contributed to the writing, and editing the manuscript, illustrations, and review of literature.

**Corresponding author: Melek Yakar, MD, Adjunct Associate Professor,** Radiation Oncology, Osmangazi University, Meşelik Campus Büyükdere District Prof. Dr. Nabi AVCI Boulevard No. 4 26040 Odunpazarı, Eskişehir 26040, Turkey. myakar@ogu.edu.tr

**Received:** December 3, 2023

**Revised:** December 16, 2023

**Accepted:** January 9, 2024

**Published online:** February 24, 2024

**Abstract**

In this editorial we comment on the article by Zhang *et al* published in the recent issue of the *World Journal of Clinical Oncology*. Pancreatic cancer is the fourth most common cause of cancer-related mortality and has the lowest survival rate among all solid cancers. It causes 227000 deaths annually worldwide, and the 5-year survival rate is very low due to early metastasis, which is 4.6%. Cancer survival increases with better knowledge of risk factors and early and accurate diagnosis. Circulating tumor cells (CTCs) are tumor cells that intravasate from the primary tumor or metastasis foci into the peripheral blood circulation system spontaneously or during surgical operations. Detection of CTC in blood is promising for early diagnosis. In addition, studies have associated high CTC levels with a more advanced stage, and more intensive treatments should be considered in cases with high CTC. In tumors that are considered radiologically resectable, it may be of critical importance in detecting occult metastases and preventing unnecessary surgeries.

**Key Words:** Pancreatic cancer; Circulating tumor cells; Prognosis; Biomarkers; Overall survival

**©The** **Author(s) 2024.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Yakar M, Etiz D. Circulating tumor cells as prognostic marker in pancreatic cancer. *World J Clin Oncol* 2024; 15(2): 165-168

**URL**: https://www.wjgnet.com/2218-4333/full/v15/i2/165.htm

**DOI**: https://dx.doi.org/10.5306/wjco.v15.i2.165

**Core Tip:** Pancreatic cancer is a cancer that is usually diagnosed at an advanced stage due to its late onset of symptoms and rapid progression, and therefore has a high mortality rate despite intensive treatments. Detecting patients at an earlier stage is important in terms of cure rates. Predicting occult metastases in radiologically resectable cases will prevent unnecessary surgery. Additionally, if the patient's prognosis can be predicted, different treatment strategies and even personalized treatments may come to the fore. Currently, there is no reliable biomarker for diagnosis, staging or prognosis prediction in pancreatic cancer. Circulating tumor cells are promising in this respect.

**INTRODUCTION**

In this editorial we comment on the article by Zhang *et al*[1]published in the recent issue of the *World Journal of Clinical Oncology*. Pancreatic cancer is the fourth most common cause of cancer-related mortality and has the lowest survival rate among all solid cancers[2]. It causes 227000 deaths annually worldwide, and the 5-year survival rate is very low due to early metastasis, which is 4.6%[3]. Survival rates increase with better recognition of risk factors, early and accurate diagnosis, and timely administration of the correct treatment. Surgery is essential for curative treatment in pancreatic cancer, but the rate of patients with resectable tumors is quite low[4]. Distant metastases are present in half of the patients at initial presentation, and 20%-30% of patients have an unsectable locally advanced tumor. Unfortunately, only 15%-20% of patients diagnosed with pancreatic cancer are considered operable. In operable patients suitable for radical excision, 5-year survival rates vary between 20%-25%[5].

Since there is no standard general population screening, the majority of patients are diagnosed after symptomatic findings. Initial symptoms such as malaise, fatigue, loss of appetite, and weight loss are often nonspecific. Jaundice associated with pancreatic cancer is the initial symptom in only 12% of patients, while jaundice develops during the course of the disease in 50% of patients. New-onset diabetes may be the first sign of pancreatic cancer. Some factors, such as tumor size, node and metastasis stage, and lymph node metastasis, affect treatment response. Although serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) levels play a helpful role in the diagnosis of pancreas, they are insufficient to predict prognosis[6]. The usefulness of biomarkers such as CA19-9 and CEA, which are commonly used in early diagnosis, is highly variable among patients[7]. New diabetes due to pancreatic cancer usually affects older patients. Sharma *et al*[8] have created an automated algorithm that uses age, weight, and blood sugar changes to select high-risk patients for pancreatic cancer screening programs. A randomized trial evaluating this algorithm is ongoing[9].

Circulating tumor cells (CTCs) are tumor cells that intravasate from the primary tumor or metastasis foci into the peripheral blood circulation system spontaneously or during surgical operations. CTCs were first discovered in 1896 and to this day have an important place in precision medicine such as cancer biology, molecular profiling and tumor liquid biopsy[10]. CTCs are also being investigated for more accurate prognosis predictions in pancreatic cancer.

**CIRCULATING TUMOR CELLS IN PANCREATIC CANCER**

CTCs are tumor cells that can enter the blood circulation system. This cellular population, along with tumor-derived new vessels, circulates through the peripancreatic vessels and their capillaries, ultimately causing metastasis in many organs. CTCs can enter the bloodstream in two ways: They are released by passive shedding from the tumor surface or through an active epithelial-mesenchymal transition mechanism. Many tumor cells are shed at the early stage of tumorigenesis *via* the primary mechanism[11]. Achieving R0 resection in pancreatic cancer is very important in the treatment of early stage localized tumors. The amount of CTCs detected in the blood before treatment may be important in making treatment-related decisions. For example, surgery without neoadjuvant treatment can be applied to patients with a low preoperative CTC burden compared to patients with a high CTC burden[12]. Identification of CTCs and differentiation of their subgroups during the treatment process may be useful in the early detection of conditions such as tumor metastasis and chemotherapy resistance[13]. In a study conducted by Okubo *et al*[14] with 40 patients diagnosed with locally advanced stage unsectable pancreatic cancer, they evaluated CTCs before and after treatment. The incidence of CTC positivity in the first three months from the start of treatments in patients with progressive and stable disease or partial response was 45.4% and 24.1%, respectively. The overall survival rate was significantly lower in patients with CTC than in patients without CTC (*P* = 0.045). To reduce the invasive examination of metastatic lesions, "liquid biopsy" of CTCs representing metastatic lesions may be a good option for diagnosis and subsequent treatment. If mutation in CTCs can be detected, resistance to treatment can be evaluated in real time[15]. In a retrospective study conducted by Tan *et al*[16], 155 patients receiving anti PD-1 immunotherapy were evaluated, and 6 out of 155 cases were advanced stage pancreatic cancer. While the disease control rate is 71% in the group of PDL1-positive CTCs, the disease control rate in the remaining cases is only 39%. In their study with 100 patients, Wei *et al*[17] examined CTC levels in peripheral blood and found positive in 76% of the patients. The decrease in follow-up CTC values during chemotherapy has been associated with response to chemotherapy.

Apart from diagnosis or treatment decision, CTCs have also been used in prognosis evaluation in pancreatic cancer.

In a study conducted by Kulemann *et al*[18], CTC was investigated in blood samples taken from healthy donors diagnosed with pancreatic cancer. While CTC positivity was detected in 11 patients (73%) diagnosed with pancreatic cancer, CTC was not detected in any of the 9 donors. According to this study, circulating tumor cells can be found in most patients with pancreatic cancer in localized, locally advanced, or metastatic disease.

In the study conducted by Gao *et al*[19] with 25 cases diagnosed with pancreatic cancer (including 5 stage I, 8 stage II, 6 stage III and 6 stage IV), CTC was studied from peripheral blood samples, and high CTC count was found to be associated with poor overall survival. According to this study, sensitivity and specificity in diagnosis with CTC are 88% and 90%. When CTC level and CA19-9 level are combined, the detection rate of pancreatic cancer can be 100%. Moreover, higher levels of CTCs successfully predict unfavorable prognosis.

In a study conducted by Court *et al*[20] with 126 patients (100 cancer, 26 benign disease), CTC was studied from venous blood samples. In this study, CTC was detected in 78% of patients diagnosed with pancreatic cancer, and as the stage progressed, the CTC level was also found to increase. In other words, a direct proportion was determined between CTC count and advanced stage. Occult metastases were detected during surgery in 13 of 53 patients who were planned for potentially curative surgery. Patients with occult metastases have statistically significantly more CTCs than patients with local disease. According to this study, CTC can determine prognosis. Additionally, CTCs show potential as a preoperative biomarker in identifying patients at high risk for occult metastatic disease.

In a study conducted by Effenberger *et al*[21] with 23 patients diagnosed with pancreatic cancer, it was revealed that CTC affected both progression-free survival and overall survival.

Studies on CTCs in pancreatic cancer have found that CTCs are associated with 1-year disease recurrence and mortality, progression-free survival and overall survival[22-24].

Diagnosis with CTC is a non-invasive procedure, does not require hospitalization, and the probability of complications is much lower than biopsy. It also has high sensitivity and specificity in diagnosis. The patient's comfort, unnecessary hospitalization time and costs will be eliminated if the diagnosis can be made with CTC. It can also provide practical guidance for treatment selection.

**CONCLUSION**

There is no screening test for pancreatic cancer today, and life expectancy in cases that are generally locally advanced or metastatic at the time of diagnosis is short despite treatments. Detection of CTC in blood is promising for early diagnosis. In addition, studies have associated high CTC levels with a more advanced stage, and more intensive treatments should be considered in cases with high CTC. In tumors that are considered radiologically resectable, it may be of critical importance in detecting occult metastases and preventing unnecessary surgeries.

**REFERENCES**

1 **Zhang ZH**, Bao YW, Zhao YJ, Wang JQ, Guo JT, Sun SY. Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis. *World J Clin Oncol* 2023; **14**: 504-517 [PMID: 38059182 DOI: 10.5306/wjco.v14.i11.504]

2 **Tjensvoll K**, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. *Int J Cancer* 2014; **134**: 1-8 [PMID: 23447365 DOI: 10.1002/ijc.28134]

3 **Zhou J**, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM. Marker expression in circulating cancer cells of pancreatic cancer patients. *J Surg Res* 2011; **171**: 631-636 [PMID: 20869080 DOI: 10.1016/j.jss.2010.05.007]

4 **Poruk KE**, Weiss MJ. The current state of surgery for pancreatic cancer. *Minerva Gastroenterol Dietol* 2015; **61**: 101-115 [PMID: 25651834]

5 **Yamamoto T**, Uchida Y, Terajima H. Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. *Asian J Surg* 2019; **42**: 93-99 [PMID: 29249392 DOI: 10.1016/j.asjsur.2017.09.003]

6 **Mirkin KA**, Hollenbeak CS, Wong J. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. *J Gastrointest Oncol* 2017; **8**: 778-788 [PMID: 29184681 DOI: 10.21037/jgo.2017.07.04]

7 **Kokhanenko NIu**, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer]. *Vopr Onkol* 2001; **47**: 294-297 [PMID: 11544826]

8 **Sharma A**, Kandlakunta H, Nagpal SJS, Feng Z, Hoos W, Petersen GM, Chari ST. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. *Gastroenterology* 2018; **155**: 730-739.e3 [PMID: 29775599 DOI: 10.1053/j.gastro.2018.05.023]

9 **Chari ST**, Maitra A, Matrisian LM, Shrader EE, Wu BU, Kambadakone A, Zhao YQ, Kenner B, Rinaudo JAS, Srivastava S, Huang Y, Feng Z; Early Detection Initiative Consortium. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. *Contemp Clin Trials* 2022; **113**: 106659 [PMID: 34954100 DOI: 10.1016/j.cct.2021.106659]

10 **Deng Z**, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. *EBioMedicine* 2022; **83**: 104237 [PMID: 36041264 DOI: 10.1016/j.ebiom.2022.104237]

11 **Hüsemann Y**, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. Systemic spread is an early step in breast cancer. *Cancer Cell* 2008; **13**: 58-68 [PMID: 18167340 DOI: 10.1016/j.ccr.2007.12.003]

12 **Luo K**, Wang X, Zhang X, Liu Z, Huang S, Li R. The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer. *Front Oncol* 2022; **12**: 933645 [PMID: 35860591 DOI: 10.3389/fonc.2022.933645]

13 **Yin L**, Pu N, Thompson E, Miao Y, Wolfgang C, Yu J. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. *Clin Cancer Res* 2021; **27**: 740-748 [PMID: 33082211 DOI: 10.1158/1078-0432.CCR-20-1746]

14 **Okubo K**, Uenosono Y, Arigami T, Mataki Y, Matsushita D, Yanagita S, Kurahara H, Sakoda M, Kijima Y, Maemura K, Natsugoe S. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. *Eur J Surg Oncol* 2017; **43**: 1050-1055 [PMID: 28233633 DOI: 10.1016/j.ejso.2017.01.241]

15 **Heitzer E**, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res* 2013; **73**: 2965-2975 [PMID: 23471846 DOI: 10.1158/0008-5472.CAN-12-4140]

16 **Tan Z**, Yue C, Ji S, Zhao C, Jia R, Zhang Y, Liu R, Li D, Yu Q, Li P, Hu Z, Yang Y, Xu J. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. *Oncologist* 2021; **26**: e2227-e2238 [PMID: 34516729 DOI: 10.1002/onco.13981]

17 **Wei T**, Zhang X, Zhang Q, Yang J, Chen Q, Wang J, Li X, Chen J, Ma T, Li G, Gao S, Lou J, Que R, Wang Y, Dang X, Zheng L, Liang T, Bai X. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. *Cancer Lett* 2019; **452**: 237-243 [PMID: 30905814 DOI: 10.1016/j.canlet.2019.03.009]

18 **Kulemann B**, Pitman MB, Liss AS, Valsangkar N, Fernández-Del Castillo C, Lillemoe KD, Hoeppner J, Mino-Kenudson M, Warshaw AL, Thayer SP. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. *Pancreas* 2015; **44**: 547-550 [PMID: 25822154 DOI: 10.1097/MPA.0000000000000324]

19 **Gao Y**, Zhu Y, Zhang Z, Zhang C, Huang X, Yuan Z. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. *J Exp Clin Cancer Res* 2016; **35**: 66 [PMID: 27066900 DOI: 10.1186/s13046-016-0340-0]

20 **Court CM**, Ankeny JS, Sho S, Winograd P, Hou S, Song M, Wainberg ZA, Girgis MD, Graeber TG, Agopian VG, Tseng HR, Tomlinson JS. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. *Ann Surg Oncol* 2018; **25**: 1000-1008 [PMID: 29442211 DOI: 10.1245/s10434-017-6290-8]

21 **Effenberger KE**, Schroeder C, Hanssen A, Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki JR, Pantel K, Bockhorn M. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer. *Clin Cancer Res* 2018; **24**: 2844-2850 [PMID: 29559560 DOI: 10.1158/1078-0432.CCR-18-0120]

22 **Bébarová L**, Skalický P, Srovnal J, Prokopová A, Zapletalová J, Hajdúch M, Loveček M. [The effect of circulating tumor cells on the survival of patients with pancreatic cancer 5-year results]. *Rozhl Chir* 2018; **97**: 94-98 [PMID: 29444581]

23 **Wang X**, Hu L, Yang X, Chen F, Xu H, Yu H, Song Z, Fei J, Zhong Z. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. *Exp Ther Med* 2021; **22**: 1140 [PMID: 34504586 DOI: 10.3892/etm.2021.10574]

24 **White MG**, Lee A, Vicente D, Hall C, Kim MP, Katz MHG, Lee JE, Ikoma N, Lucci A, Tzeng CD. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. *Ann Surg Oncol* 2021; **28**: 4615-4622 [PMID: 33415562 DOI: 10.1245/s10434-020-09518-y]

**Footnotes**

**Conflict-of-interest statement:** All the authors have no commercial associations or sources of support that might pose a conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 3, 2023

**First decision:** December 7, 2023

**Article in press:** January 9, 2024

**Specialty type:** Oncology

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Qu S, China **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Yu HG



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** office@baishideng.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2024 Baishideng Publishing Group Inc. All rights reserved.**